Bystander killing of cancer requires the cooperation of CD4+ and CD8+ T cells during the effector phase
Open Access
- 4 October 2010
- journal article
- Published by Rockefeller University Press in The Journal of Experimental Medicine
- Vol. 207 (11) , 2469-2477
- https://doi.org/10.1084/jem.20092450
Abstract
Cancers frequently evade cytotoxic T lymphocyte–mediated destruction through loss or down-regulation of tumor antigens and antigen-presenting major histocompatibility complex molecules. Therefore, we have concentrated our efforts on immunological strategies that destroy nonmalignant stromal cells essential for the survival and growth of cancer cells. In this study, we developed a non–T cell receptor transgenic, immunocompetent tumor model to determine whether tumor-bearing hosts’ own immune systems could eliminate cancer cells through stromal targeting and what role CD4+ T cells play alongside CD8+ T cells in this process. We found that aggressive cancers could be eradicated by T cell targeting of tumor stroma. However, successful elimination required the cooperation of CD4+ and CD8+ T cells not only during the induction phase but also during the effector phase in the tumor microenvironment, implying a new role for CD4+ T cells that has not been previously described. Our study demonstrates the potential of stromal targeting as a cancer immunotherapy and suggests that successful anticancer strategies must facilitate cooperation between CD4+ and CD8+ T cells at the right times and the right places.Keywords
This publication has 50 references indexed in Scilit:
- Genomic Instability Within Tumor Stroma and Clinicopathological Characteristics of Sporadic Primary Invasive Breast CarcinomaJAMA, 2007
- COOPERATION BETWEEN CD4+AND CD8+T CELLS: When, Where, and HowAnnual Review of Immunology, 2006
- Human CD4+ Effector Memory T Cells Persisting in the Microenvironment of Lung Cancer Xenografts Are Activated by Local Delivery of IL-12 to Proliferate, Produce IFN-γ, and Eradicate Tumor CellsThe Journal of Immunology, 2005
- Molecular characterization of the tumor microenvironment in breast cancerCancer Cell, 2004
- Human CD4+ effector T cells mediate indirect interleukin-12- and interferon-gamma-dependent suppression of autologous HLA-negative lung tumor xenografts in severe combined immunodeficient mice.2002
- T Cell Receptor Recognition of MHC Class II–Bound Peptide Flanking Residues Enhances Immunogenicity and Results in Altered TCR V Region UsageImmunity, 1997
- Rat mammary adenocarcinoma 13762 expressing IFN-gamma elicits antitumor CD4+ MHC class II-restricted T cells that are cytolytic in vitro and tumoricidal in vivo.The Journal of Immunology, 1995
- Effect of anti-CD4 on CD4 subsets. I. Anti-CD4 preferentially deletes resting, naive CD4 cells and spares activated CD4 cells.The Journal of Immunology, 1994
- aberrant expression of HLA Class‐I antigens in burkitt lymphoma cellsInternational Journal of Cancer, 1991
- Identification of the T-cell and Ia contact residues of a T-cell antigenic epitopeNature, 1987